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Background: Breast cancer is the second most lethal cancer in women. Understanding biological mechanisms that
cause progression of this disease could yield new targets for prevention and treatment. Recent experimental
studies suggest that brown adipose tissue (BAT) may play a key role in breast cancer progression. The primary
objective for this pilot study was to determine if the prevalence of active BAT in patients with breast cancer is
increased compared to cancer patients with other malignancies.
Methods: We retrospectively analyzed data from 96 breast cancer patients who had FDG PET/CT scan for routine
staging at the University of Maryland and 96 age- and weight-matched control female patients with other
malignancies (predominantly colon cancer) who had undergone FDG PET/CT imaging on the same day. Data on
the distribution (bilateral upper neck, supraclavicular and paraspinal regions) and intensity (SUVmax) of active BAT
were evaluated by 2 Nuclear Medicine physicians, blinded to the clinical history.
Results: We found sufficient evidence to conclude that based on our sample data the prevalence of active BAT in
breast cancer patients’ group is significantly different from that in the control group. The estimated frequency of BAT
activity was 3 fold higher in breast cancer patients as compared to controls with other cancers, (16.7% vs. 5.2%,
respectively, p = 0.019). When patients were stratified by age in order to determine the possible impact of age related
hormonal changes on active BAT among the younger women (≤ 55 years of age), 25.6% breast cancer patients
exhibited BAT activity compared to only 2.8% in control women (p = 0.007). In contrast, among the older women
(> 55 years of age), the prevalence of active BAT was similar among breast cancer and control women (10.7% vs 6.7%).
Conclusions: In breast cancer patients prevalence of BAT activity on FDGPET/CT is 3-fold greater than in age- and body
weight-matched patients with other solid tumor malignancies; this difference is particularly striking among younger
women aged < =55. In summary, our retrospective clinical data provide support to pursue prospective
clinical and translational studies to further define the role of BAT in breast cancer development and progression.
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Breast cancer is the second most lethal cancer in women
[1]. Early stage breast cancers that are confined to the
layer of cells in the breast lobule or duct where they
originated have a better prognosis and can be cured [1].
However, the prognosis for advanced stage cancers that
have invaded locally and spread to other parts of the body* Correspondence: wchen5@umm.edu; ljone010@umaryland.edu
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reproduction in any medium, provided the oris poor, with median survival averaging 18–24 months [1].
Understanding biological mechanisms that could affect
the possible progression of breast cancer from the high
risk lesions such as atypical ductal or lobular hyperplasia
to noninvasive cancers, ductal and lobular carcinoma in
situ to invasive cancers could yield new targets for preven-
tion of breast cancer and treatment of more advanced
stages and ultimately improve patient survival.
Once considered inert, adipose tissue has emerged as a
key player in cancer development and progression [2].
Adipocyte-derived factors have been shown to both stimu-
late or inhibit cell growth and cause systemic inflammation. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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searchers worldwide to focus on the link between obesity
or dysfunctional white adipose tissue (WAT) and cancer
[2-7]. Yet another type of fat, brown adipose tissue (BAT),
has recently emerged as an interest in context of cancer
and tumor development as well [4,5]. BAT is characterized
by its multilocular cells, numerous mitochondria, and high
vascularity, functions to dissipate energy as heat in re-
sponse to cold temperatures [8]. Studies in mice have
shown that the activation of BAT is associated with the
synthesis and secretion of angiogenic and growth fac-
tors, resulting in markedly increased vascular density
due to activation of angiogenesis [9,10]. Therefore, re-
search investigating the potential role of active BAT in
adults should also be accounted for in the context of
cancer and tumor development.
Data on connections of BAT with neoplasms of nona-
dipocytic origin is limited. In humans, BAT was consid-
ered only to be of significance in infants as a source of
easily accessible energy that would regress and gradually
be replaced by WAT with age [8]. Yet, emerging studies
point to a potential association of specific BAT features
to certain mutated tumor suppressor genes [4,11]. In par-
ticular, we observed a significantly increased deposition of
BAT in the adult mammary fat pad of a mouse model of
Breast Cancer gene 1 (BRCA1) breast cancer compared to
age-matched mammary glands from wildtype mice [11].
This was quite abnormal considering that high amounts
BAT are usually only in the mammary gland from birth
until about 8–10 weeks of age (near the completion of pu-
berty) [12,13]. Considering that high amounts of BAT are
exclusively detected in the mouse early in mammary gland
development, particularly during stages of ductal growth
and increased estrogen signaling, one can speculate that
BAT may play a role in mammary ductal growth. More-
over, the high level of BAT in the mammary gland of these
mice was associated with increased angiogenesis [11].
Indeed it is known that angiogenesis is an essential step
for breast cancer progression and dissemination [14].
Therefore, the unexpected finding of the sustained BAT
phenotype in the mammary gland of adult mice predis-
posed to breast cancer raises an important issue of
whether there is a relationship between high levels of
BAT and breast cancer. Although such a possibility has
not been explored clinically, this is an important next
step to determine the value and relevance of our find-
ings for human breast cancer.
18 F-fluorodeoxyglucose (FDG) Positron Emission Tom-
ography/Computerized Tomography (PET/CT) is a widely
used modality of imaging glucose metabolism in cancer
cells for staging of primary cancer and detection of distant
metastasis in patients [15,16]. Due to its similar biological
properties of hypermetabolism to cancer cells, BAT may
also have intense FDG uptake and can be as a “false-positive” for cancer evaluation if detected on PET/CT
[15-17]. In the current, study we used FDG PET/CT as a
non-invasive approach to determine whether there is a sig-
nificant difference between FDG uptake in BAT between
patients with breast cancer and those scanned for other
malignancies. The primary objective for this retrospective
pilot study was to explore the patterns of BAT activity with
FDG PET/CT in patients with breast cancer with a broader
aim to form a basis for further studies that will help to de-
termine whether BAT may be an important determinant
for breast cancer risk and progression. We also provide an
appreciation of the site-based distribution of BAT observed
in the images and the clinical and pathological characteris-
tics of the groups of patients in this study.
Methods
Patients
This retrospective image and chart/medical record
review study was approved by the University of Maryland
Baltimore Institutional Review Board (IRB). The Institutional
review board waived the need to obtain consent from
patients. Patients were undergoing their FDG PET/CT
scans as part of routine standard of care and no changes to
standard of care were made. We reviewed the distribution
and intensity (maximum standard uptake value, SUVmax)
of BAT on FDG PET/CT scans in a total of 96 breast
cancer patients who had PET/CT scans from October
2010 to September 2012 in our institution. If a patient had
multiple PET/CT scans during this interval, only the first
PET/CT scan was analyzed to avoid over counting BAT
rate in the same patient. For comparison, each breast
cancer patient was assigned a paired-control of a non
breast cancer patient (mainly colon cancer) who had a
PET/CT scan on the same day. Both groups were carefully
matched in reference to sex (all female), age (± 5 years),
and body weight (± 5 kg) to control for some of the known
factors that could potentially affect FDG uptake in BAT.
FDG PET/CT imaging
Patients fasted for at least 4 h before PET/CT imaging
and had a measured finger stick glucose level less than
220 mg/dl before the administration of FDG. As routine
practice, patients with fasting blood glucose level greater
than 220 mg/dl were excluded from study as high glu-
cose may interfere with 18 F-FDG tracer uptake based
on the imaging guidelines. Scans were acquired approxi-
mately 60 min after the injection of about 555 MBq
(15 mCi) FDG with the Gemini PET/CT (Philips Medical
Systems, Cleveland, Ohio, USA) scanner with a 16-slice
Brilliance CT.
Data collection
The distribution of the BAT was analyzed in the breast
cancer patients (n = 96) and the non-breast cancer patients
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cine physicians blinded to the clinical history. Training and
expertise of the two nuclear medicine physicians reading
FDG PET/CT was 7 years and 3 years, respectively, with
an interpersonal variation of 0. The interpretation of a
positive active BAT site on PET/CT was based on the im-
aging findings of focal FDG uptake in adipose tissue that is
visually more intense than the surrounding muscle activity,
which is simple “yes” or “no” with no case showing equivo-
cal findings. No SUVmax threshold value was set to define
a positive BAT. The location of the BAT was recorded
in the bilateral neck, supraclavicular and paraspinal re-
gions. The SUVmax of brown fat was measured, a posi-
tive BAT case was defined as at least one positive BAT
site in any of the locations in the neck, supraclavicular
or paraspinal regions.
Statistical analysis
The prevalence of positive BAT cases on FDG PET/CT
in the breast cancer patients was estimated and com-
pared to the control patients using the Fisher’s exact test
for 2×2 tables. The Fisher-Freeman-Halton test with
Monte-Carlo simulations was applied for rxc contin-
gency tables. Plausible risk factors were also estimated
using the logistic regression approach. The distribution of
BAT was compared using the non-parametric approach,
the Wilcoxon test. The ANOVA method was applied to
assess the differences of SUVmax of BAT in different loca-
tions between the 2 study groups. All statistical tests were
two-sided and done at the 0.05 level of significance.




Generally BAT occurrence on FDG PET/CT is thought
to be related to several factors, inclucing sex, age and
temperature [8,9]. Notably, BAT is inversely correlated
with obesity and body mass index (BMI) [8,9]. To con-
trol these factors, in the current study, we assigned each
breast cancer patient a paired control with an FDG PET/
CT scan done on the same day for other cancers (mainly
colon cancer), matched with sex, age and body weight.
The BAT prevalence rate is 5.2% in the control group in
the current study, similar to the reported 2.3-10% in the
general population [8,9]. The non breast cancer patients
(n = 96) consisted of colorectal cancer (n = 54), lung
cancer (n = 13), lymphoma (n = 12), head neck cancer
(n = 7), pancreatic cancer (n = 6) and others (n = 4, GIST
2, leiomyosarcoma 1, and carcinoid 1). Mean age was
58.6 ± 11.4 in the breast cancer and 58.2 ± 12.3 in the
controls, and mean body weight (kg) was 66.4 ± 9.6 in
the breast cancer and 70.0 ± 10.8 in the controls. There
were no significant differences between the mean ages inthe subgroups: [age ≤ 55 yrs: Breast cancer 46.3 +/− 6.7
vs. Non breast cancer 47.9 ± 6.5, p = 0.288] and [age >
55 yrs: Breast cancer 65.9 ± 8.3 vs. Non breast cancer
66.1 ± 7.4, p = 0.878].
Relationship between levels of BAT and breast cancer
In adults, BAT is thought to normally remain inactive
and thus does not appear on FDG PET/CT unless stim-
ulated, such as exposure to cold temperature (15–17). In
the current clinical study, we demonstrate that the preva-
lence of metabolically active BAT as seen on FDG PET/
CT is higher in breast cancer patients than their paired
controls with other malignancies. Among the breast can-
cer group, there was 16/96 (16.7%) BAT positive cases
compared to only 5/96 (5.2%) positive cases among the
non breast cancer control group. The prevalence of BAT
in the breast cancer group was about 3-fold higher than
that in the non breast cancer control group (p = 0.019)
(Figure 1A). To find out if possible changes in age related
sex hormone levels may have an effect on BAT, we strati-
fied the data by age (≤ 55 and > 55 ) to approximately div-
ide the subjects into pre and post-menopausal groups. We
found that the difference in BAT prevalence associated
with ≤ 55 years old patients was greater in the breast can-
cer group (10/39 = 25.6%) than in the non breast cancer
control (1/36 = 2.8%) (p = 0.007). In contrast, among those
who were > 55 years old, the difference in BAT prevalence
in the breast cancer group (6/57 = 10.5%) and the non
breast cancer control group (4/60 = 6.7%) (p = 0.522) was
no longer observed (Figure 1B). Although we are not able
to obtain each patient’s history of menopausal status given
the retrospective nature of our study, the findings of age
related increase in BAT uptake suggest that sex hormone
levels may play a role in the development of brown fat
and breast cancer.
There are two other studies that have indicated high
levels of 18 F-FDG uptake in breast cancer populations. In
one small retrospective study, Rousseau et al. used PET/
CT to evaluate early response to neoadjuvant chemother-
apy for breast cancer in 33 patients with breast cancer
[18]. They reported that 35% of PET/CT images (12 out
of 33) from breast cancer patients were positive for active
metabolism in BAT [18]. Most recently in a larger retro-
spective study, Cronin et al., studied the prevalence of
BAT in patients with different types of cancer and found
that the prevalence of active BAT was highest in patients
with breast cancer and sarcomas [19]. To the best of our
knowledge, this is the first that directly compared the
prevalence of active BAT in breast cancer patients with
their paired age- and weigh-matched controls. We ac-
knowledge that without immunohistochemical confirm-
ation, FDG PET/CT may markedly underestimate true
prevalence of BAT. Thus, it is unknown whether FDG





































Figure 1 Prevalence of BAT case in the breast cancer and control patients. (A) Expression of BAT was compared in the 96 breast cancer
patient and 96 paired control patients with other cancers, using exact Fisher’s test. A positive case is defined as at least 1 site of BAT in any
location of the neck, supraclavicular and paraspinal region. (B) Stratification of the brown fat prevalence by age of ≤ 55 and > 55 years old to
roughly divide the patients into pre- and post-menopausal groups.
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applies to both the cancer and control groups.
Mechanisms for a potential association between active
BAT and breast cancer are not entirely clear and currently
under investigation. We suggest two alternate hypotheses.
First, BAT could participate as an active participant in the
progression of breast cancer. Given its high vascularity
and ability to secrete bioactive molecule [9,10]. BAT could
potentially cause nearby pre-cancerous epithelial cells to
proliferate more rapidly, accelerating the progression of
breast cancer. Alternatively, BAT could participate as a
passive participant in the progression of breast cancer.
Considering cancer cells are also known to secrete bio-
active molecules to support its own progression [20], acti-
vation of BAT could be secondary to the breast cancer.
Site-based distribution of BAT and clinical and
pathological characteristics
The site distribution of BAT found in the common dis-
tinct anatomical locations among the patient groups are
reported in Table 1. There was no difference in the dis-
tribution of BAT in the 6 locations of the left and right
neck, left and right supraclavicular, and paraspinal re-
gions between the breast cancer and the non breast can-
cer control groups (Table 1). In addition, no difference
of BAT FDG uptake (mean of SUVmax) was found in
each of the locations or in any of the sites between the 2
groups. Previously, we had shown that there were signifi-
cant differences in the deposition of BAT in the adultTable 1 Site-based distribution of brown fat seen on FDG






Left Right Left Right Left Right
Breast cancer 4 4 10 9 12 8 47
Control 3 2 3 3 2 1 14
Total 7 6 13 12 14 9 61mammary fat pad of a mouse model of breast cancer
compared to age-matched mammary glands from wild-
type mice [12].
In contrast to rodents, there is only limited under-
standing of the distribution of BAT within the human
breast. Multilocular adipocytes resembling brown adipo-
cytes have been detected in postmortem human infant
breasts. [21,22]. Albeit rare, the observation of brown fat
tumors (hibernomas) in the breast have been described
[23-27]. We also acknowledge that activation of BAT tis-
sue within the breasts in female patients undergoing
FDG PET/CT is typically not seen. This could be due to
the heterogeneity of cell types within the breast com-
pared to the homogenous cell types in BAT. Interest-
ingly, studies have shown that exposure of humans and
rodents to cold activates thermogenic activity in brown
adipose tissue (BAT) [10,28]. Biopsies from mice also
show that this BAT activation causes an obvious transi-
tion from subcutaneous white adipose tissue (WAT) into
brown-like adipose tissue (BRITE or BEIGE). If this
phenomenon also occurs in humans, than the breast
cancer patients positive for active BAT in common re-
gions are more likely to show brown-like adipose tissue
within their subcutaneous breast adipose tissue biopsies.
However, in the current study, we did not explore this
hypothesis. Therefore, it would be most ideal to examine
breast tissue slides from patient biopsies by H&E or for
immunohistochemical markers for BAT to determine if
there are cells that resemble the morphology and mo-
lecular characteristics of brown adipocytes, respectively.
Finally, we assessed whether there was a relationship
between BAT and disease stage, histological type and
tumor stage in breast cancer patients. The available clin-
ical and pathologic data are reported in Table 2. Although
significant differences in the clinical and tumor patho-
logical characteristics (stage, histologic grade, estrogen re-
ceptor (ER), progesterone receptor (PR), BRCA1 status)
could not be determined in this retrospective study, we do
see higher prevalence of Human Epidermal Growth Factor
Table 2 Clinical and pathological characteristics in breast
cancer patients with and without brown fat
Brown fat + Brown fat +
Race
White 7 (43.8) 38 (47.5)
Black 6 (37.5) 39 (48.8)
Other 3 (18.7) 3 ( 3.7)
Tumor size (cm) 3.26 ± 1.85 3.38 ± 1.74
Tumor histology (%)
Ductal 14 (87.5) 59 (73.8)
Adeno 0 (0.0) 1 ( 1.3)
Lobular 0 (0.0) 9 (11.3)
Unknown 2 (12.5) 11 (13.7)
Nodal metastasis
Positive 8 (50.0) 32 (40.0)
Negative 3 (18.8) 17 (21.3)
Unknown 5 (31.2) 36 (45.0)
Distant metastasis
Positive 8 (50.0) 44 (55.0)
Negative 8 (50.0) 36 (45.0)
Stage
I 0 4 ( 5.0)
II 3 (18.8) 15 (18.8)
III 3 (18.8) 9 (11.3)
IV 10 (52.5) 45 (56.3)
Unknown 0 7 ( 8.7)
ER
Positive 10 (62.5) 42 (52.5)
Negative 4 (25.0) 27 (33.8)
Unknown 2 (12.5) 11 (13.8)
PR
Positive 7 (43.8) 36 (45.0)
Negative 6 (37.5) 33 (41.3)
Unknown 3 (18.7) 11 (13.7)
HER2
Positive 6 (37.5) 12 (15.0)
Negative 7 (43.8) 54 (67.5)
Unknown 3 (18.7) 14 (17.5)
Grade
I 0 4 ( 5.0)
II 5 (31.3) 15 (18.8)
III 7 (43.8) 28 (35.0)
Unknown 4 (25.0) 33 (41.2)
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cancer cases. Notably, in the breast cancer group, the BAT
positive patients tend to have a 2-fold higher HER2positive rate (6/16 = 37.5%) than the BAT negative pa-
tients (12/96 = 15.0%) (P = 0.06), but this did not reach
statistical significance.
Multiple factors contributing to FDG uptake in BAT
have been described in the literature [16,17,20]. While
care was taken to control for some of the known factors
that could potentially affect FDG uptake in BAT includ-
ing matching study participants for age, sex, weight, and
same day of scan between groups, due to the retrospect-
ive nature of this study, complete clinical data were not
available for each patient. Therefore, we acknowledge
several limitations to this study including the unavail-
ability of the actual menopause status, and the timing of
prior medication and treatment history of every patient.
Additionally, considering the majority of the control pa-
tients had colorectal cancer, it is important to note that
obesity is a well known risk factor for colorectal cancer
[29]. Lower prevalence of BAT tissue in patients with
colon cancer may be related to obesity because subjects
with BAT tend to be those who are leaner [29]. Thus,
while both breast cancer and control group were matched
in reference to body weight, it does not measure obesity
making it a possible confounding variable in this study.
We recognize that in our study, the uptake tissue was not
biopsied to validate the presence of BAT. Therefore, FDG
PET/CT could potentially underestimate or overestimate
the true prevalence of BAT. Nevertheless, the correlation
of uptake in hypermetabolic BAT is well-supported and a
recognized feature of FDG PET. Further, we anticipate
that any “underestimation or overestimation” would apply
to both the cancer and control groups [15-19]. In the fu-
ture, it will be worthwhile to conduct a prospective study
in larger patient population. This would afford the oppor-
tunity to collect information and samples from all subjects
thereby potentially eliminating some of the confounding
variables in the evaluation of the results.
Conclusions
We have conducted a retrospective investigation using
non-invasive FDG PET/CT imaging to explore the rela-
tionship between levels of BAT presence and breast can-
cer in adult women. Early indications show that there is
an increased prevalence of metabolically active BAT seen
on FDG PET/CT in breast cancer patients compared to
their pair matched control patients with other cancers.
This finding is most prevalent in younger premenopausal
patients, indicating a possible role of sex hormones. These
clinical data provide further support to our experimental
studies that BAT is associated with breast cancer, however
further studies are required to clarify a potential mechan-
ism. We believe that our investigations to determine
whether BAT plays an active or passive role in breast
cancer progression will provide future insight on whether
breast cancer patients who are positive for FDG uptake in
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